Back to results
US 10,633,427 B2Granted
Diagnosis and therapy of multiple sclerosis
AssigneePrindex S.R.L.
InventorsRoberto Paterno, Mariarosaria Santillo, Vittorio Enrico Avvedimento, Luigi Michele Pavone
Life of this patent
Estimating the term…
Abstract
The serotonin receptor 5HT2A (5HT2aR) and membrane NADPH oxidases (NOX enzymes) are found to be a target of autoantibodies present in Multiple Sclerosis patients. The present invention refers to peptides comprised in the extracellular regions of the human 5HT2aR and/or NOXs for diagnosis and therapy of Multiple Sclerosis.
Claims13
A peptide consisting of an amino acid sequence having at least 90% identity with DDSKVFKEGS (SEQ ID NO:
- 157), wherein the peptide is able to bind multiple sclerosis auto-antibodies.
A nucleic acid molecule encoding a peptide consisting of an amino acid sequence having at least 90% identity with DDSKVFKEGS (SEQ ID NO:
- 157), wherein the peptide is able to bind multiple sclerosis auto-antibodies.
Dependencies are inferred from the claim text.